Blog › process chemistry

C4X3256 (Rocavorexant): First Scale-Up Campaign for a Selective Orexin-1 Receptor Antagonist — Process Intelligence Dossier

De-risking an in-licensed route: Indivior and Almac's convergent 10-stage, 29.2 kg scale-up of the selective orexin-1 antagonist C4X3256 (rocavorexant), with T3P replacing the acid-chloride endgame.

The problem: inherit a route, then make it manufacturable

When Indivior in-licensed the selective orexin-1 receptor (OX₁R) antagonist program C4X3256 (INDV2000, rocavorexant) from C4X Discovery, it inherited a route that had delivered two early batches (480 g, then a 4.2 kg cGMP lot) at excellent purity — but with a list of scale-up liabilities: a telescoped Stage 1/2 of “complex equilibria,” a LiAlH₄ amide reduction, an mCPBA oxidation, a highly toxic TMSCN step, a structural-alert pyridine N-oxide (ICH M7), a corrosive SOCl₂ acid-chloride endgame, and high-molecular-weight salt intermediates that forced salt-break operations. This is the archetypal post-in-licensing problem: a chemistry that works is not yet a chemistry you can run.

The strategy: a convergent 10-stage route, two halves joined by T3P

Convergent 10-stage route to C4X3256 (rocavorexant): amine 6 + acid 10 united by a T3P coupling. Redrawn by Astinova Bio Labs (RDKit); no paper figures reused.

The campaign kept the molecule’s convergent logic and rebuilt the operations around it. Two advanced intermediates are made in parallel and united in the final stage:

  • Amine 6 — five stages from L-alaninamide·HCl: reductive amination (PhCHO), N-methylation, amide→amine reduction, S_NAr onto 2-chloro-5-(trifluoromethyl)pyrazine, then debenzylation.
  • Acid 10 — four stages from 5-bromo-2-methylpyridine: Cu-catalyzed Ullmann N-arylation with 1,2,3-triazole (N2-regioselective), N-oxidation, a Reissert-type cyanation (TMSCN/BzCl) installing the C-2 nitrile, and hydrolysis.
  • Final coupling — the two fragments joined with T3P / iPr₂NEt in EtOAc to give C4X3256 monohydrate in 80%.

The process intelligence: what actually changed

Liability in the inherited routeScale-up fix
Stage 1/2 telescope = “complex equilibria,” low/variable yieldIsolate crystalline amine 2 as a control point; revised Stage 1 (PhCHO/NaOH/Pd-C, MeOH) completes in 1–2 h
Poorly crystallizing amide intermediate 3Telescope Stages 2→3 in THF, avoiding its isolation
High-MW trimesic-acid salt of 6 forcing a salt breakImproved 6 and 10 so the final amide forms without a preliminary salt break
mCPBA N-oxidationPeracetic acid
SOCl₂ acid-chloride endgame (corrosive, water-sensitive)T3P coupling — equimolar acid 10 / amine 6, EtOAc, 35–45 °C

The toxic steps that remain are handled, not hidden: the TMSCN/BzCl cyanation (HCN risk) runs cold with controlled addition, and all cyanide-containing waste is quenched, basified, and consigned for licensed disposal. The resulting N-oxide (ICH M7 alert) is carried as a transient, purged downstream.

The outcome

Two GMP batches delivered 14.4 kg (77%) and 14.8 kg (80%) — 29.2 kg total, ~78% average for the final stage — of C4X3256 monohydrate (Form 1) as white acicular needles, 99.7–99.8% HPLC and 100% ee. KF (3.8–4.0% w/w H₂O) confirmed the monohydrate (theory 4.1%); drying was capped at 50 °C to protect the hydrate. Tightening the crystallization concentration pulled D90 from 311 µm (prior lot) to 52 µm — a formulation-ready particle size out of the final step.

The drug substance itself: N,6-dimethyl-3-(2H-1,2,3-triazol-2-yl)-N-[(2S)-1-{[5-(trifluoromethyl)pyrazin-2-yl]amino}propan-2-yl]pyridine-2-carboxamide (anhydrous C₁₈H₁₉F₃N₈O, MW 420.4), isolated as the 1:1 hydrate.

Why it matters

  • A textbook de-risking. New crystalline control points, two telescopes, and reagent swaps (peracetic acid for mCPBA, T3P for SOCl₂) turned an inherited medicinal-chemistry route into a kilogram-scale GMP process.
  • Convergence pays. Building amine 6 and acid 10 separately and coupling last keeps the longest linear sequence short and the high-value fragments protected.
  • Particle engineering at the API step. Hitting Form 1 monohydrate with a 52 µm D90 straight from crystallization is the kind of endgame control that formulation teams actually ask for.

Reference: Breen, G. F.; Carey, J. S.; Claveau, R.; Maczka, M. “Synthesis of a Selective Orexin 1 Receptor Antagonist: First Scale-Up Campaign Following In-Licensing.” Org. Process Res. Dev. 2026, DOI: 10.1021/acs.oprd.6c00444. (Work by Indivior and Almac Sciences; NIDA award UG3DA050308.)

Source article is CC-BY-NC-ND — no paper figures are reused here. Both visuals are original to Astinova Bio Labs: the convergent route and all structures redrawn with RDKit/Matplotlib.

Astinova Bio Labs develops and de-risks synthetic routes like this one — convergent design, reagent and safety swaps, telescoping, and crystallization/particle control. Talk to us about your process.